Introduction 1
Along with recent advances in human pluripotent stem cells (hPSCs) (Avior et 2 al., 2016; Shi et al., 2017) , genome engineering in hPSCs has shown great potential 3 for gene correction in the context of regenerative medicine (Hockemeyer and Jaenisch, 4 2016). The use of hPSCs derived from patients with genetic disorders enables a 5 constant supply of certain types of cells that mimic the pathology of interest (i.e., 6 disease modeling), and can thus make valuable contributions to both drug screening 7 and basic studies (Engle and Puppala, 2013; Hockemeyer and Jaenisch, 2016) . 8
However, patient-derived induced PSCs (iPSCs) require large numbers of case and 9 control iPSCs to minimize the effects of variability among unrelated hPSC lines. By 10 contrast, genome-edited hPSCs provide isogenic pairs of control and disease model 11 cells, enabling rigorous comparisons (Hendriks et al., 2016; Merkle and Eggan, 2013; 12 Musunuru, 2013) . 13
Despite the great potential of genome engineering in hPSCs, the extremely 14 low efficiency of this procedure, along with the time-consuming and laborious 15 procedures required for clonal selection, remains a critical obstacle to a wide range of 16 applications, such as pooled sgRNA screening, which can be performed in mouse 17
ESCs (Koike-Yusa et al., 2014) . Another factor contributing to this technical barrier is 18 the fact that Cas9 activity in hPSCs is low (Mali et al., 2013) ; moreover, the cells 19 undergo massive p53-dependent cell death in response to DNA damage by effect of 20 Cas9 (Ihry et al., 2018) . Multiple strategies have been developed to address the low 21 efficiency of genome editing in hPSCs (as well as in other somatic cell models): 22 inducible Cas9 systems (Cao et al., 2016; Gonzalez et al., 2014) , puromycin selection 23 (Steyer et al., 2018) , self-replicating episomal vectors (Xie et al., 2017) , and so on. 24
Alternatively, enriched selection of a minority of the target-edited clones has been 25
Results 1

High expression of SLC35F2 mediates intracellular uptake of YM155 in hPSCs 2
Selective induction of cell death in hPSCs by YM155, which decreases 3 teratoma formation (Bedel et al., 2017; Kang et al., 2017; Kim et al., 2017; Lee et al., 4 2013b) , is associated with the DNA damage response (Lee et al., 2013b) . Cytotoxicity 5 of YM155 cannot be fully prevented by suppression of BIRC5 (which encodes 6 survivin) (Sim et al., 2017) . Hence, we sought to identify the mechanism underlying 7 selective cell death of hPSCs. To this end, we took advantage of bulk cancer cell line 8 gene expression data and drug response data from the Cancer Cell Line Encyclopedia 9 (CCLE) and Cancer Therapeutics Response Portal (CTRP), respectively. First, using 10 data from gene expression omnibus (GEO) (Table. S1), we identified a hPSC 11 signature, i.e., a set of genes that are differentially expressed in hPSCs relative to their 12 differentiated counterparts. Using the hPSC signature, we calculated hPSC scores 13 (Materials and Methods in detail) for 666 human cancer cells by performing single-14 sample Kolmogorov-Smirnov (KS) enrichment analysis. By correlating the hPSC 15 scores with the sensitivities of each cell line to each of 543 compounds, we identified 16 YM155 as the most effective drug in cells with high hPSC scores (Fig. 1B) ; this 17 implies that YM155 should be highly specific for hPSCs, as demonstrated previously 18 (Bedel et al., 2017; Kang et al., 2017; Kim et al., 2017; Lee et al., 2013b) . Based on 19 correlation of drug and gene expression signature (Fig. 1A) , genes whose expression 20 was highly correlated with sensitivity to YM155 were identified as described 21 previously (Rees et al., 2016) . SLC35F2, a membrane solute carrier, was the transcript 22 most correlated with YM155 sensitivity (Fig. 1B, left panel) , suggesting that cellular 23 import of YM155 by SLC35F2 is responsible for the highly selective cytotoxicity of 24 the drug in hPSCs (Lee et al., 2013b) ; this is consistent with previous reports in 25 cancer models (Nyquist et al., 2017; Radic-Sarikas et al., 2017; Winter et al., 2014) . 1 Using a database of gene expression profiles (http://nextbio.com) (Kupershmidt et al., 2 2010), we compared relative SLC35F2 expression between 24 human embryonic stem 3 cells (hESCs) and various cancer cell lines; PC-3, a human prostate cancer cell line, 4 was used as a positive control (P.C.) for high expression of SLC35F2 (Winter et al., 5 2014) . As shown in Figure 1C , all hESCs (including H9, mainly used in this study) 6 expressed SLC35F2 at higher levels than the other cancer cell lines, consistent with a 7 previous study that identified hESC surface marker proteins (Kolle et al., 2009 ). On 8 the other hand, mesenchymal stem cells derived from hESCs (hESC-MSCs) and 9 human dermal fibroblasts (hDFs), which are both highly resistant to YM155 treatment 10 
SLC35F2 is responsible for YM155-induced selective cell death in hPSCs 21
To explore the connection between the selective cytotoxicity of YM155 in 22 hPSCs (EC 50 : 10 nM, Fig. S1B ) and the high expression of SLC35F2 in these cells 23 (Figs. 1D, E , and S1A), we knocked out SLC35F2 in hESCs using CRISPR/Cas9 by 24 targeting exon 7, as previously described (Winter et al., 2014) (Fig. 2A) . After 25 introducing a single guide RNA (sgRNA) against SLC35F2 along with Cas9, we 1 treated the cells with YM155 to ablate wild-type hESCs that had not been edited. 2
Following YM155 treatment, a few colonies survived, whereas most cells underwent 3 cell death (Fig. 2B, red arrow) . One of the surviving colonies (Fig. 2B, YM155 -4 resistant clone: YM155R) was selected and maintained. Clone YM155R was highly 5 resistant to further YM155 treatment (Fig. 2B, right panel) . Furthermore, after 6 introduction of the sgRNA against SLC35F2 and Cas9, insertion/deletion (indel) 7 frequency was increased in a concentration-dependent manner (Fig. 2C) , and in the 8 presence of 100 nM YM155, the surviving clones were nearly 100% genome-edited 9 hESCs (100% indel) (Fig. 2D) , suggesting that the SLC35F2 knockout (SLC35F2 10 KO) hESC population was enriched in a dose-dependent manner, thereby efficiently 11 eliminating false positives (i.e., hESCs that survived with wild-type SLC35F2). A 12 single clone from YM155R maintained under YM155 treatment turned out to be a 13 homozygous bi-allelic SLC35F2 KO (Fig. 2E ). This clone (SLC35F2 KO hESCs: 14 KO#1) was highly resistant to YM155-induced cell death ( Fig. 2F and Movie S1). 15
However, like control hESCs, it underwent dramatic cell death in response to 16 bleomycin (BLM), which is imported by SLC22A16, another member of the solute 17 carrier family (Aouida et al., 2010) (Fig. S1C) . We concluded that the acquired 18 resistance of SLC35F2 KO hESCs to YM155 was the result of low intracellular levels 19 of YM155 due to failure of drug uptake (Fig. 2H ) and subsequent fewer DNA damage 20 response in the absence of SLC35F2 (Fig. 2G) . 21
To characterize the SLC35F2 KO hESCs, we monitored the expression levels 22 of typical pluripotency markers such as NANOG, SOX2, and POU5F1. Consistent 23 with the absence of alteration of typical pluripotency markers (Fig. 3A) , protein levels 24 of SOX2, OCT4, and LIN28A (Figs. 3B and S1D), as well as alkaline phosphatase 25 activity (Fig. 3C) , were not significantly altered in SLC35F2 KO hESCs. Consistent 1 with this, self-renewal of SLC35F2 KO hESCs was also maintained, as reflected by 2 their growth rate (Figs. 3D and S1E), fluorescence-based competition assay with WT 3 control ( Fig. 3E) (Cha et al., 2017) , and in vitro and in vivo differentiation potentials 4 (Figs. 2F and G) . In support of these findings, comparison of transcriptome data from 5 WT and KO hESCs revealed a linear relationship in the expression levels of 6 pluripotency genes (Korkola et al., 2006 ) (red circles) (Fig. 3H) . 7 8
YM155-mediated enriched selection 9
The observation that enriched selection of SLC35F2 KO hESCs could be 10 achieved by YM155 treatment led us to predict that induced resistance to YM155 11 could be useful for isolating genome-edited hPSCs if SLC35F2 were co-targeted with 12 the gene of interest (GOI) (Fig. 4A) . For a proof-of-concept study, we took advantage 13 of HEK293T cells, which express relatively high levels of SLC35F2 (Fig. S2A) , 14 leading to dose-dependent cell death following YM155 treatment (10-fold higher 15 EC 50 than for hESCs, Fig. S2B ). Simple introduction of sgRNA for SLC35F2 along 16 with Cas9, followed by YM155 treatment, led to establishment of a genome-edited 17 population ( Fig. 4B ) at up to 88.4% efficiency (Fig. 4C ). Like hESCs, SLC35F2 KO 18 HEK293T cells were highly resistant to YM155, but not doxorubicin ( Fig. S2C and 19 D), due to failure of cellular uptake of YM155 (Fig. S2E) . 20
Next, we attempted co-targeting of SLC35F2 along with the CCR5. In these 21 experiments, we took advantage of the CCR5 surrogate reporter system (Ramakrishna 22 et al., 2014) to monitor the efficiency of CCR5 targeting. In this system, the 23 monomeric red fluorescent protein (mRFP) is expressed constitutively, whereas 24 expression of green fluorescent protein (GFP) is initiated only after CCR5 is targeted 25 by Cas9 expression (Fig. 4D) . Thus, the proportion of GFP-positive cells enables live 1 monitoring of CRISPR/Cas9 targeting efficiency. After co-targeting SLC35F2 and 2 CCR5, followed by YM155 treatment, we observed a significant increase in the GFP-3 positive population (Figs. 4E and F) . Considering that the surrogate reporter system 4 reveals only one-third of the genome-edited population (Ramakrishna et al., 2014) , 5 the ~25% GFP-positive population following YM155 selection implied a genome-6 edited population as high as 80% (Fig. 4F ). It is also noteworthy that YM155 7 treatment eliminated most mRFP-expressing cells (red box), thereby selectively 8 enriching for GFP-positive cells (blue box) (Fig. S2F , Movies S1 and S2). To confirm 9 enrichment of CCR5 KO by co-targeting of SLC35F2 followed by YM155 treatment, 10
we performed the T7 endonuclease 1 (T7E1) assay for CCR5; the results revealed a 11 distinct increase in KO efficiency (Fig. 4G) . 12 13
YM155-based enriched selection of genome-edited hESCs 14
After testing this approach (YM155-based Enriched Selection of CRISPR Co-15 target; hereafter, 'YES-approach') in HEK293T cells (Fig. 4 ), we applied it to hPSCs, 16 which are more sensitive to YM155 (Figs. 1 and 2). For proof-of-concept of the YES-17 approach, we attempted to produce CCR5-targeted hESCs. We chose this gene for the 18 following reasons: (i) disruption of CCR5 (a genomic safe harbor (Sadelain et al., 19 2011)) has little effect on the pluripotency of hPSCs (Kang et al., 2015) ; and (ii) the 20 cells would have potential future applications in HIV-1 research, e.g., production of 21 Holt et al., 2010; Hutter et al., 2009; Lai, 2012) . In 22 these experiments, we used two different ratios of sgRNAs targeting CCR5 and 23 SLC35F2 to minimize the selection of false-positive clones (e.g., 24
CCR5WT/SLC35F2KO) that could still survive under YM155 treatment. Through the 25 YES-approach with sgRNA targeting CCR5 (C) and SLC35F2 (S), seven (for 1 C:S=1:1 ratio) or four (C:S=2:1) colonies survived and were isolated. Among them, 2 three clones and one clone, respectively, were CCR5-targeted hESCs (over 25% 3 efficiency) (Fig. 5A ). Accordingly, a single clone after the selection was shown as 4 85.5% indel occurred, implying that the surviving clones were successfully genome-5 edited in the desired manner (Fig. 5B) . 6
Although overall gene expression and expression of pluripotency genes were 7 not altered in SLC35F2 KO hESCs (Fig. 3H ), we could not rule out the effect of 8 permanent KO of SLC35F2 in hESCs. Therefore, we closely examined the genes 9 whose expression was altered in SLC35F2 KO cells. Although we detected only 10 minor differences between wild-type (NC#1 and NC#2) and KO cells (KO#1 and 11 KO#2) in both overall transcription and the hPSC signature, expression of genes 12 involved in 'cellular transition metal ion homeostasis,' which are associated with the 13 original function of SLC35F2 as a membrane transporter, was altered significantly 14 ( Fig. 5C and Table. 
S2). 15 16
Scarless YES-approach for establishment of CCR5-targeted hESCs 17
Although the YES-approach was effective for establishing GOI-targeted 18 hESCs, permanent KO of SLC35F2 to induce YM155 resistance would be 19 problematic from the standpoint of isogenic disease modeling because the effects of 20 SLC35F2 on mineral or ion homeostasis ( Fig. 5C and Table S2 ) could not be ruled 21 out. To address this complication, transient induced YM155 resistance mediated by 22 depletion of SLC35F2 was achieved by introduction of a siRNA against SLC35F2 23 along with the sgRNA targeting the GOI (in this case, CCR5) (Fig. 6A) . As predicted, 24 depletion of SLC35F2 had fully recovered 5 days after siRNA transfection (Fig. 6B) . 25 Induced YM155 resistance disappeared at the same time (Fig. 6C, right panel) , 1 allowing for enriched selection at 2 days after siRNA transfection (Fig. 6C, left panel) . 2
These observations suggest that induced YM155 resistance mediated by siRNA 3 against SLC35F2 occurred transiently, with no permanent scar. 4
We then applied this scarless YES-approach to CCR5 gene editing in hESCs. 5
As shown in Figure 6D , CCR5 target efficiency was improved in a YM155 dose-6 dependent manner. Notably in this regard, the indel percentage in samples with the 7 YES-approach reached 72.2% even without laborious isolation of numerous single 8 colonies (Figs. S3A-D) . Accordingly, the mutation patterns of the genome-edited 9 population were simplified by treatment with 20 nM YM155, indicating that few 10 colonies survived the treatment (Figs. 6E and S3E) . One of the clones obtained from 11 the YES-approach was correctly targeted to CCR5 (Figs. 6F and S3F) . Also, the 12 CCR5 targeted clone maintained pluripotency as determined by alkaline phosphatase 13 activity and expression level of pluripotency markers (Fig. S3G) . Along with recovery 14 of SLC35F2 expression (Fig. S3G) , the cytotoxicity of YM155 was fully restored 15 In order to avoid the laborious procedures made necessary by the extremely 2 low efficiency of genome editing using current techniques, a variety of strategies have 3 been developed to improve editing efficiency not only in hPSCs (Gonzalez et al., 4 2014; Mitzelfelt et al., 2017; Steyer et al., 2018) , but also in somatic cell models 5 (Agudelo et al., 2017; Cao et al., 2016; Liao et al., 2015) . Among them, enriched 6 selection approaches based on inducing drug resistance by targeting the causative 7 gene responsible for drug sensitivity (Agudelo et al., 2017; Liao et al., 2015) would 8 be advantageous because selection of desirable clones results from altered phenotype 9 (e.g., induced drug resistance) caused by effect of gene editing unlike puromycin 10 selection, corresponding to merely Cas9 expression (Steyer et al., 2018) . In these 11 procedures, however, induced drug resistance was achieved by producing a 12 permanent scar in the causative genes (Agudelo et al., 2017; Liao et al., 2015) , 13 potentially resulting in unexpected bias in hPSCs-based disease models. 14 Here, we demonstrated that selective induction of cell death in hPSCs by 15 YM155 (Lee et al., 2013b) results from selective cellular uptake of the drug due to 16 high expression of SLC35F2 (Figs. 1 and S1A) . The high cytotoxicity of YM155 was 17 completely abolished by knockout of SLC35F2 (Fig. 2) , and the induction of YM155 18 resistance by knockout of SLC35F2 was useful for enriched selection of genome-19 edited clones (Figs. 4 and 5) . Live monitoring revealed that un-targeted cells 20 underwent cell death in response to YM155 (Fig. S2F, Movies S2 and S3) . 21
Considering the undesirable biases that could result from permanent knockout of 22 SLC35F2 (Fig. 5) , we then attempted to temporarily induce YM155 resistance by 23 transient knockdown of SLC35F2, and we found that this was sufficient to achieve 24 enriched selection of targeted clones (Fig. 6) . The function of SLC35F2 in the edited 25 clones was fully recovered (Fig. 6) . Following this scarless YES-approach, CRISPR-1 targeted clones were achieved with up to 72.2% efficiency, avoiding the need for 2 laborious clonal selection within 3 weeks. 3
It is important to note that YM155 sensitivity varies depending on cell type 4 due to differences in the expression level of SLC35F2 (Fig. S2A) as well as the 5 sensitivity of the DNA damage response. The high expression level of SLC35F2 in 6 most hPSCs (Kolle et al., 2009) (Fig. 1C) may render the YES-approach uniquely 7 suitable for application in these cells. In addition, the strong mitochondria-dependent 8 apoptotic cell death response of hPSCs by genotoxic stresses (Liu et al., 2013) , which 9 depends on mitochondrial translocation of p53 (Lee et al., 2013b) , may contribute to 10 the high selectivity of YM155: as previously reported (Winter et al., 2014) , 11 intracellular YM155 taken up through SLC35F2 induced a clear DNA damage 12 response (Fig. 1G) . Unlike other chemical-based selection approaches, induced 13 YM155 resistance was achieved by abrogating a drug-specific membrane importer, 14 thereby blocking cellular uptake of YM155. Thus, due to their failure to take up 15 YM155, clones that survived enriched selection would be free from undesirable 16 effects of YM155. 17
However, the scarless YES-approach requires colony selection to avoid false-18 positive clones (Fig. 5A) 
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STAR Methods 1
Pharmacogenomics data sets 2
Basal-level cell line mRNA expression data was obtained from the Cancer 3
Cell
Line Encyclopedia (CCLE) data portal 4 1 (Gibco) media and plated on Matrigel-coated plate. 10 µM of Y27632 (Gibco) was 2 added for cell attachment when needed. HEK293T cells were cultured on a culture 3 dish (Falcon) fed with DMEM (Gibco) added with 10% FBS (Gibco) and 50 µg/ml 4 Gentamicin. Upon transfer, HEK293T cells were rinsed with DPBS and detached 5 enzymatically with 0.25% Trypsin. Trypsin was inactivated by adding DMEM 6 containing 10% FBS and appropriate cells were seeded on the dishes. 
RNA-sequencing analysis 18
Total RNA was extracted from cells using Easy-BLUE TM RNA isolation kit 19 (iNtRON Biotechnology) and quality control was performed. The qualified samples 20 proceed to library construction. The sequencing library is prepared by random 21 fragmentation of the DNA or cDNA sample, followed by 5' and 3' adapter ligation. 22
The read quality of raw RNA-seq files (FASTQ) was checked using FastQC (v0.11.7) 23 and the adapter sequences in reads were eliminated using cutadapt (v1.8.1). Trimmed 24 FASTQ files were aligned to GRCh38 genome using STAR aligner (v2.6.0a), then the 25
